Dr. Gerber on the Future Landscape of Radiation Oncology

Naamit K. Gerber, MD
Published: Tuesday, Jul 24, 2018



Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses the future landscape of radiation oncology.

The impending TAILOR RT trial will be using Oncotype to stratify patients and see if they need regional nodal irradiation or no regional nodal irradiation. Patients who have undergone a lumpectomy will get whole breast radiation versus whole breast plus regional nodal radiation. Patients who have undergone a mastectomy will either receive no radiation or radiation to the chest wall plus nodal radiation, explains Gerber.

The trial is seeking to understand which subgroups will benefit most from regional nodal irradiation. Researchers are using Oncotype as a surrogate to try to identify the patients with a worse biology. This is based on some data that shows that Oncotype not only correlates with distant recurrence but also with locoregional recurrence, says Gerber.

There is also more of a push to explore the use of hypofractionated radiation in patients who have had a mastectomy. It has become more widely adopted in early-stage breast cancer patients with intact breast, states Gerber. Partial breast radiation is commonly used at NYU Langone's Perlmutter Cancer Center, but is not as widespread as expected. In August 2017, Lancet Oncology published a large study from the United Kingdom comparing partial breast to whole breast radiation in almost 2000 patients showing equivalent outcomes. Gerber hopes that partial breast radiation becomes more common as the data accumulate.


Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses the future landscape of radiation oncology.

The impending TAILOR RT trial will be using Oncotype to stratify patients and see if they need regional nodal irradiation or no regional nodal irradiation. Patients who have undergone a lumpectomy will get whole breast radiation versus whole breast plus regional nodal radiation. Patients who have undergone a mastectomy will either receive no radiation or radiation to the chest wall plus nodal radiation, explains Gerber.

The trial is seeking to understand which subgroups will benefit most from regional nodal irradiation. Researchers are using Oncotype as a surrogate to try to identify the patients with a worse biology. This is based on some data that shows that Oncotype not only correlates with distant recurrence but also with locoregional recurrence, says Gerber.

There is also more of a push to explore the use of hypofractionated radiation in patients who have had a mastectomy. It has become more widely adopted in early-stage breast cancer patients with intact breast, states Gerber. Partial breast radiation is commonly used at NYU Langone's Perlmutter Cancer Center, but is not as widespread as expected. In August 2017, Lancet Oncology published a large study from the United Kingdom comparing partial breast to whole breast radiation in almost 2000 patients showing equivalent outcomes. Gerber hopes that partial breast radiation becomes more common as the data accumulate.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Publication Bottom Border
Border Publication
x